We found that KPA treatment in insulin-resistant wild-type C57BL/6J mice and DIAMOND mice reduced hepatic steatosis, decreased liver enzyme ALT, and reduced serum TGs, FFA, and cholesterol. This evidence concerns the gene GPT and fatty liver disease.